RUNX1 and acute myeloid leukemia: Similarly, no impact of RUNX1 mutations on any outcome parameter was observed when the analysis was restricted to specific subgroups: 18 patients who underwent HLA-matched sibling HSCT, 79 patients (87%) with de novo AML, or 55 patients (76%) with intermediate-risk cytogenetics (Supplementary Table S4, Supplementary Figures S2 and S3).